Literature DB >> 19018242

Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes.

Fausto J Rodriguez1, Caterina Giannini, Yan W Asmann, Mukesh K Sharma, Arie Perry, Kathleen M Tibbetts, Robert B Jenkins, Bernd W Scheithauer, Shrikant Anant, Sarah Jenkins, Charles G Eberhart, Jann N Sarkaria, David H Gutmann.   

Abstract

Pilocytic astrocytomas (PAs) are World Health Organization Grade I gliomas; they most often affect children and young adults and occur in patients with neurofibromatosis type 1 (NF1). To identify genes that are differentially expressed in sporadic (S-PA) versus NF1-associated PAs (NF1-PAs) and those that might reflect differences in clinical behavior, we performed gene expression profiling using Affymetrix U133 Plus2.0 GeneChip arrays in 36 S-PAs and 11 NF1-PAs. Thirteen genes were overexpressed, and another 13 genes were underexpressed in NF1-PAs relative to S-PAs. Immunohistochemical studies performed on 103 tumors, representing 2 independently generated tissue microarrays, confirmed the differential expression of CUGBP2 (p = 0.0014), RANBP9 (p = 0.0075), ITGAV1 (p = 0.0001), and INFGR1 (p = 0.024) proteins. One of the underexpressed genes, aldehyde dehydrogenase 1 family member L1 (ALDH1L1), was also reduced in clinically aggressive compared with typical PAs (p = 0.01) and in PAs with increased cellularity and necrosis. Furthermore, in an additional independent set of tumors, weak to absent ALDH1L1 expression was found in 13 (72%) of 18 clinically aggressive PAs, in 8 (89%) of 9 PAs with pilomyxoid features, in 7 (70%) of 10 PAs with anaplastic transformation, and in 16 (76%) of 21 diffusely infiltrating astrocytomas of various grades. In summary, we have identified a molecular signature that distinguishes NF1-PA from S-PA and found that ALDH1L1 underexpression is associated with aggressive histology and/or biologic behavior.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19018242      PMCID: PMC2730602          DOI: 10.1097/NEN.0b013e31818fbe1e

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  43 in total

1.  Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma.

Authors:  I Goldberg; B Davidson; R Reich; W H Gotlieb; G Ben-Baruch; M Bryne; A Berner; J M Nesland; J Kopolovic
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

2.  Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas.

Authors:  L Kluwe; C Hagel; M Tatagiba; S Thomas; D Stavrou; H Ostertag; A von Deimling; V F Mautner
Journal:  J Neuropathol Exp Neurol       Date:  2001-09       Impact factor: 3.685

3.  Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging.

Authors:  C F Parsa; C S Hoyt; R L Lesser; J M Weinstein; C M Strother; R Muci-Mendoza; M Ramella; R S Manor; W A Fletcher; M X Repka; J A Garrity; R N Ebner; M L Monteiro; R M McFadzean; I V Rubtsova; W F Hoyt
Journal:  Arch Ophthalmol       Date:  2001-04

4.  Ki-67: a prognostic factor for low-grade glioma?

Authors:  Barbara J Fisher; Elitza Naumova; Christopher C Leighton; George N Naumov; Nancy Kerklviet; David Fortin; David R Macdonald; J Gregory Cairncross; Glenn S Bauman; Larry Stitt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

5.  Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas.

Authors:  David H Gutmann; Nicolé M Hedrick; Jun Li; Rakesh Nagarajan; Arie Perry; Mark A Watson
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

6.  Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma.

Authors:  M K Sharma; M A Watson; M Lyman; A Perry; K D Aldape; F Deák; D H Gutmann
Journal:  Neurology       Date:  2006-01-10       Impact factor: 9.910

7.  HIPK2 associates with RanBPM.

Authors:  Ying Wang; E Marion Schneider; Xin Li; Irina Duttenhöfer; Klaus Debatin; Hubert Hug
Journal:  Biochem Biophys Res Commun       Date:  2002-09-13       Impact factor: 3.575

8.  A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma.

Authors:  Christoph Burkhard; Pier-Luigi Di Patre; Danielle Schüler; Georges Schüler; M Gazi Yaşargil; Yasuhiro Yonekawa; Urs M Lütolf; Paul Kleihues; Hiroko Ohgaki
Journal:  J Neurosurg       Date:  2003-06       Impact factor: 5.115

9.  10-formyltetrahydrofolate dehydrogenase, one of the major folate enzymes, is down-regulated in tumor tissues and possesses suppressor effects on cancer cells.

Authors:  Sergey A Krupenko; Natalia V Oleinik
Journal:  Cell Growth Differ       Date:  2002-05

10.  Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age.

Authors:  David T W Jones; Koichi Ichimura; Lu Liu; Danita M Pearson; Karen Plant; V Peter Collins
Journal:  J Neuropathol Exp Neurol       Date:  2006-11       Impact factor: 3.685

View more
  23 in total

1.  Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma.

Authors:  Xiao-Qian Chen; Juan-Ru He; Hui-Yun Wang
Journal:  Med Oncol       Date:  2011-10-11       Impact factor: 3.064

2.  MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2.

Authors:  Cheng-Ying Ho; Eli Bar; Caterina Giannini; Luigi Marchionni; Matthias A Karajannis; David Zagzag; David H Gutmann; Charles G Eberhart; Fausto J Rodriguez
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

3.  Phenotypic variations in NF1-associated low grade astrocytomas: possible role for increased mTOR activation in a subset.

Authors:  Mark Jentoft; Caterina Giannini; Ling Cen; Bernd W Scheithauer; Bridget Hoesley; Jann N Sarkaria; Patrice C Abell-Aleff; Erika F Rodriguez; Ying Li; Fausto J Rodriguez
Journal:  Int J Clin Exp Pathol       Date:  2010-12-12

4.  PI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.

Authors:  Erika F Rodriguez; Bernd W Scheithauer; Caterina Giannini; Amanda Rynearson; Ling Cen; Bridget Hoesley; Heather Gilmer-Flynn; Jann N Sarkaria; Sarah Jenkins; Jin Long; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2010-11-28       Impact factor: 17.088

Review 5.  Loss of ALDH1L1 folate enzyme confers a selective metabolic advantage for tumor progression.

Authors:  Sergey A Krupenko; Natalia I Krupenko
Journal:  Chem Biol Interact       Date:  2019-02-20       Impact factor: 5.192

Review 6.  CELFish ways to modulate mRNA decay.

Authors:  Irina Vlasova-St Louis; Alexa M Dickson; Paul R Bohjanen; Carol J Wilusz
Journal:  Biochim Biophys Acta       Date:  2013-01-15

Review 7.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

8.  Insulin-like growth factor 2 mRNA binding protein 3 expression is an independent prognostic factor in pediatric pilocytic and pilomyxoid astrocytoma.

Authors:  Valerie N Barton; Andrew M Donson; Diane K Birks; Bette K Kleinschmidt-DeMasters; Michael H Handler; Nicholas K Foreman; Sarah Z Rush
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

Review 9.  Pathological and molecular advances in pediatric low-grade astrocytoma.

Authors:  Fausto J Rodriguez; Kah Suan Lim; Daniel Bowers; Charles G Eberhart
Journal:  Annu Rev Pathol       Date:  2012-10-29       Impact factor: 23.472

Review 10.  Molecular neuropathology of gliomas.

Authors:  Markus J Riemenschneider; Guido Reifenberger
Journal:  Int J Mol Sci       Date:  2009-01-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.